Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MediSwipe Inc. Announces First eCommerce Sales of Hemp Based Energy Drink "Chillo" on Amazon.com
LOS ANGELES, June 13, 2013 /PRNewswire/ -- MediSwipe Inc. (www.MediSwipe.com) (OTCQB: MWIP), a data management solutions company for the medicinal marijuana and health care industry, today announced that the Company's popular hemp based energy drink "CHILLO" is now for sale with the world's largest online retailer on Amazon.com Marketplace. With the trusted Amazon platform and fulfillment services, MediSwipe expects to experience a surge in orders of the beverage through ecommerce sales as the products profit from enhanced visibility within the Amazon catalog.
"Chillo is a one of a kind product, and can only benefit from being placed in front of tens of millions of potential customers. Amazon.com offers an opportunity to reach a niche market as we can now service customers across North America and abroad. As we expand the brand globally, we are proud to partner with the largest and most successful online marketplace around the world," stated MediSwipe CEO, B. Michael Friedman.
With the dramatic orange color and flavor of CHILLO, and added benefits of hemp, vitamins and caffeine, we are pleased to be able to deliver the product through Amazon.com for those who are not able to access it through our retail network," stated B. Michael Friedman for MediSwipe.
The Company has also announced plans to launch additional online marketing campaigns through its Facebook site for both "Chillo" and C+ Swiss Tea. Starting today, for every 420th "Like" to the Company's Facebook page, the Company will give away a free Chillo and C+Swiss gift pack to that lucky friend.
CHILLO, with its distinct trademark orange can, carries the chill of hemp seed extract with the added punch and perfect blend of caffeine, vitamins B6 and B12 for the ultimate drink experience. Both Chillo and C+ Swiss Hemp Tea are available in dispensaries and select locations across the country, and may be ordered exclusively through MediSwipe by calling 248.262.6850 or through email at info@MediSwipe.com.
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2013, FQ4/13 Revenues Highest in Corp
Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral abuse-resistant controlled release product formulations and the manufacturing of generic pharmaceuticals, announced results for the fiscal year ended March 31, 2013.
Consolidated revenues were $3.4 million for the fiscal year, an increase of $1.0 million or approximately 40% over consolidated revenues for the prior year. Revenues for the quarter ended March 31, 2013, were exceptionally strong, totaling $1.5 million, the highest quarterly revenue level in corporate history, 131% above quarterly revenues for the comparable period of the prior year. The large increases in revenues are the result of the successful launch and strong growth in new product revenues which have mostly been created during the past 18 months.
Since the end of the fiscal year, Elite launched two new products, Phentermine 15mg capsules and Phentermine 30mg capsules, both being distributed under license by TAGI Pharma. These new products did not generate revenues during the fiscal year ended March 31, 2013, but are generating revenues currently. Shortly, Elite will begin manufacture of naltrexone 50 mg tablets, a recently approved ANDA whose revenues are not represented in Elite's fiscal year 2013 results.
Message board...................... DD Facts:Cord Blood America Announces 2012 Financial Results
LAS VEGAS, April 1, 2013 /PRNewswire/ -- Cord Blood America, Inc. (www.cordblood-america.com) (OTC Bulletin Board: CBAI) ("CBAI" or the "Company") today announced financial results for the year ended December 31, 2012.
Full Year Ended December 31, 2012 Highlights
Revenue increased 18% to a record $6.0 million from $5.1 million in the year ago period.
Gross Profit increased 20% to $4.2 million from $3.5 million in the year ago period.
SG&A decreased 17% or $1.1 million to $5.6 million in 2012 from $6.7 million in 2011.
Total assets exceeded total liabilities by $0.52 million, a net change of $1.4 million from the prior year of 2011 where the liabilities outpaced company assets.
Net cash balance increased over 116% to $393,832 from the year ago period.
Positive cash flow from operations of $0.19 million, an improvement of 117% compared to the year ago period.
Cord Blood America Announces 2012 Financial Results
LAS VEGAS, April 1, 2013 /PRNewswire/ -- Cord Blood America, Inc. (www.cordblood-america.com) (OTC Bulletin Board: CBAI) ("CBAI" or the "Company") today announced financial results for the year ended December 31, 2012.
Full Year Ended December 31, 2012 Highlights
Revenue increased 18% to a record $6.0 million from $5.1 million in the year ago period.
Gross Profit increased 20% to $4.2 million from $3.5 million in the year ago period.
SG&A decreased 17% or $1.1 million to $5.6 million in 2012 from $6.7 million in 2011.
Total assets exceeded total liabilities by $0.52 million, a net change of $1.4 million from the prior year of 2011 where the liabilities outpaced company assets.
Net cash balance increased over 116% to $393,832 from the year ago period.
Positive cash flow from operations of $0.19 million, an improvement of 117% compared to the year ago period.
Cord Blood America Announces 2013 First Quarter Financial Results
LAS VEGAS, May 15, 2013 /PRNewswire/ -- Cord Blood America, Inc. (www.cordblood-america.com) (OTC Bulletin Board: CBAI) ("CBAI" or the "Company") today announced financial results for the quarter ended March 31, 2013.
First Quarter 2013 Highlights From Continuing Operations
Recurring revenues increased approximately 7% for the three months ended March 31, 2013 to $740,124.
Cash provided by operations totaled $128,970 in the first quarter. This represents 68% of the total full year cash generated in 2012 of $190,323.
EBITDA for the quarter increased 587% to $99,985 from $14,542 in the year ago period.
SG&A decreased 11% to $1.11 million from $1.24 million in the year ago period.
Our cash balance increased 40% to $369,186 compared to the same period a year ago.
Cord Blood America Announces 2013 First Quarter Financial Results
LAS VEGAS, May 15, 2013 /PRNewswire/ -- Cord Blood America, Inc. (www.cordblood-america.com) (OTC Bulletin Board: CBAI) ("CBAI" or the "Company") today announced financial results for the quarter ended March 31, 2013.
First Quarter 2013 Highlights From Continuing Operations
Recurring revenues increased approximately 7% for the three months ended March 31, 2013 to $740,124.
Cash provided by operations totaled $128,970 in the first quarter. This represents 68% of the total full year cash generated in 2012 of $190,323.
EBITDA for the quarter increased 587% to $99,985 from $14,542 in the year ago period.
SG&A decreased 11% to $1.11 million from $1.24 million in the year ago period.
Our cash balance increased 40% to $369,186 compared to the same period a year ago.
EPGL Medical Unveils New Devices and Intellectual Property Under EP Global Communications, Inc. Ownership
IRVINE, Jun 18, 2013 (GLOBE NEWSWIRE via COMTEX) - via PRWEB - EP Global Communications, Inc. (the Company), (Stock Ticker: EPGL) EPGL Medical Sciences, is pleased to announce several new devices resulting from the TopSpin technology recently announced. Many of these devices have not been revealed before today. To Compliment the MPDD, the new MPTT will be first to become a prototype this fall and new FDA 510k and PMA Applications are being prepared for filing during 3rd and 4th Quarters. EPGL has filed patents and owns unique Intellectual Property for each of the following new smart medical devices:
1. A new advanced ablation device for nerve pain treatment in the back.
2. A new advanced ablation device for nerve treatment of Facial Glabballar Frowning.
3. A new advanced device for elimination of facial wrinkles.
4. A new advanced Epidural device.
5. A new advanced power source for TopSpin medical devices.
6. A new and promising device for treatment of Retinitis Pigmentosa
7. A new and promising device for treatment of Macular Degeneration
8. A new and promising treatment for Hearing Loss
9. A new more accurate treatment for trigger points in the muscles (MPTT)
10. A new advanced device for treatment of prostate tumors.
11. A new advanced endoscopic device.
12. A new advanced device for delivery of micron sized drug payloads.
13. A new advanced device for delivery of micro mechanical devices into the body.
14. A new advanced device for biopsy.
15. A new advanced device for stem cell treatment delivery.
16. A new advanced contact lens device.
Several more devices beyond this list will be revealed in coming months by the Company. This represents the beginning for EPGL technological development.
About EP Global Communications, Inc. / EPGL Medical
EP Global Communications, Inc. is a medical device manufacturer and marketing company with exclusive rights to a new FDA 510k cleared medical device called the Muscle Pain Detection Device. The MPDD is a revolutionary new diagnostic tool for the detection of muscular originated pain in the human body.
EP Global Communications, Inc. is a medical device manufacturer and marketing company with exclusive rights to a new FDA 510k cleared medical device called the Muscle Pain Detection Device. The MPDD is a revolutionary new diagnostic tool for the detection of muscular originated pain in the human body.
Bottom of this article it states FDA approved:
Google Glass to be Integrated by Medical Device Maker EPGL Med and EP Global Communications, Inc.
IRVINE, Apr 11, 2013 (GLOBE NEWSWIRE via COMTEX) - via PRWEB - EP Global Communications, Inc. (the Company), (stock ticker:EPGL) will be among the first Medical Device Makers to Implement Google Glass technology and the API Mirror platform for use with its medical devices. EPGL Medical, a new medical device maker specializing in advanced technology for innovative hand-held medical devices, has several new devices in development under direction of David T. Markus Ph.D., which are being developed with the latest smart platforms in mind. "Physicians using our devices will be able to utilize technology such as Google Glass while performing procedures, using our devices and viewing feedback data in real-time." Said David T. Markus, Ph.D. "The advancement of these exceptional new technologies are ideal for medical applications as doctors need a hands-free reference to feedback data while performing procedures." Markus said.
In addition to integrating smart technology such as Google Glass, EPGL Medical now has a "secret weapon" medical device technology advancement which no other medical device company has. This single technology will be the catalyst for dozens of new medical device technologies to be produced or licensed by the Company. The Company is in the process of filing more than 50 patents to protect this unique and valuable innovation. "It so happens that our new devices are being developed right at the same time very cool smart technologies such as Google Glass are in their infancy". Said Company President Michael Hayes. "It makes sense to embrace this technology fully and use it to make EPGL medical devices even smarter. Every new device concept we are developing will benefit from the integration of smart technology."
In addition to the new technologies EPGL is progressing, the Company is implementing an innovative new approach to medical device marketing with a business model which guarantees residual income from each new device sold. The Company's VIP approach to its physician customers with on-going technical support and educational training, will build strong loyalty to our medical devices.
Additionally, EPGL is making it as attractive as possible to purchase our devices by giving doctors and hospitals several affordable options for their purchase including, outright purchase, leasing and financing options. These options combined with the newly established CPT coding for our first device; MPDD, will make it easier than ever for doctors to build a business around EPGL medical devices.
About EP Global Communications, Inc. / EPGL Medical
EP Global Communications, Inc. is a medical device manufacturer and marketing company with exclusive rights to a new FDA 510k cleared medical device called the Muscle Pain Detection Device. The MPDD is a revolutionary new diagnostic tool for the detection of muscular originated pain in the human body.
Tier Change
Thu, Jul 04, 2013 12:00 - Entest BioMedical Inc. (ENTB: OTCQB) - Tier Change - The symbol, ENTB, no longer is classified as OTC Pink Limited. As of Thu, Jul 04, 2013, ENTB resides in the OTCQB tier. You may find a complete list of tier changes at otcmarkets.com.
MediSwipe Inc. Announces First eCommerce Sales of Hemp Based Energy Drink "Chillo" on Amazon.com
LOS ANGELES, June 13, 2013 /PRNewswire/ -- MediSwipe Inc. (www.MediSwipe.com) (OTCQB: MWIP), a data management solutions company for the medicinal marijuana and health care industry, today announced that the Company's popular hemp based energy drink "CHILLO" is now for sale with the world's largest online retailer on Amazon.com Marketplace. With the trusted Amazon platform and fulfillment services, MediSwipe expects to experience a surge in orders of the beverage through ecommerce sales as the products profit from enhanced visibility within the Amazon catalog.
"Chillo is a one of a kind product, and can only benefit from being placed in front of tens of millions of potential customers. Amazon.com offers an opportunity to reach a niche market as we can now service customers across North America and abroad. As we expand the brand globally, we are proud to partner with the largest and most successful online marketplace around the world," stated MediSwipe CEO, B. Michael Friedman.
With the dramatic orange color and flavor of CHILLO, and added benefits of hemp, vitamins and caffeine, we are pleased to be able to deliver the product through Amazon.com for those who are not able to access it through our retail network," stated B. Michael Friedman for MediSwipe.
The Company has also announced plans to launch additional online marketing campaigns through its Facebook site for both "Chillo" and C+ Swiss Tea. Starting today, for every 420th "Like" to the Company's Facebook page, the Company will give away a free Chillo and C+Swiss gift pack to that lucky friend.
CHILLO, with its distinct trademark orange can, carries the chill of hemp seed extract with the added punch and perfect blend of caffeine, vitamins B6 and B12 for the ultimate drink experience. Both Chillo and C+ Swiss Hemp Tea are available in dispensaries and select locations across the country, and may be ordered exclusively through MediSwipe by calling 248.262.6850 or through email at info@MediSwipe.com.
About MediSwipe Inc.
MediSwipe Inc. (www.MediSwipe.com) provides innovative patient solutions for electronically processing transactions within the healthcare industry. MediSwipe provides terminal-based service packages and integrated Web Portal add-ons for physicians, clinics, hospitals and medical dispensaries that include: digital patient records, Electronic Referrals, Credit/Debit Card merchant services, Check Guarantee and Accounts Receivable Financing.
CopyTele Acquires Rights to Patent Portfolio Covering Loyalty Programs
MELVILLE, NY--(Marketwired - April 03, 2013) - CopyTele, Inc. ("CTI") (OTCQB: COPY) (OTCBB: COPY) today announced that its wholly owned subsidiary, CTI Patent Acquisition Corporation, has acquired the rights to a patent portfolio relating to loyalty awards programs commonly provided by airlines, credit card companies, hotels, retailers, casinos, and others. The portfolio covers the conversion of non-negotiable, loyalty awards points into negotiable funds used to purchase goods and services from third parties, and the conversion of awards points into points and awards provided by other loyalty program providers. Estimates indicate that there are over 2 billion memberships to loyalty awards programs in the United States.
Robert Berman, CTI's President and CEO stated, "Our acquisition of the rights to these 13 patents fits perfectly with our strategy of building a diversified collection of patent portfolios with significant monetization potential. We have begun the process of transforming CTI into a world class, publicly traded, patent assertion company."
About CopyTele, Inc.
CopyTele develops and acquires patented technologies for the purposes of patent monetization and patent assertion. The company currently has 5 patent portfolios in the areas of Key Based Encryption, E-Paper® Electrophoretic Display, Nano Field Emission Display ("NFED"), Micro Electro Mechanical Systems Display ("MEMS"), and Loyalty Point Conversion Systems. Additional information is available at www.CTIpatents.com.
Elite Pharmaceuticals Awarded Second U.S. Patent for Abuse Resistant Drug Formulation
Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced the issuance of U.S. Patent No. 8,425,933 entitled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof" by the United States Patent and Trademark Office. This is the second issued U.S. patent covering Elite's abuse resistant technology for opioid products. Elite has additional patents pending in the U.S., Canada and Europe.
"We are pleased to receive this second abuse resistant patent. The recent guidances and actions by the FDA related to extended release opioids and specifically oxycodone demonstrates the FDA support for abuse resistant technologies. Opioid products incorporating abuse resistant technologies have become a public health priority and these recent actions appear to be a major step towards the FDA eventually requiring that all extended release opioids utilize these technologies. This validates our approach and we believe substantially increases the value of our intellectual property and the abuse resistant products in our pipeline," said Jerry Treppel, Elite's Chairman and CEO.
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products. Elite's strategy includes assisting partner companies in the life cycle management of products to improve off-patent drug products and developing generic versions of controlled release drug products with high barriers to entry. Elite has three commercial products currently being sold, three additional products approved and soon to be launched, and one additional product pending approval by the FDA. Elite's lead pipeline products include abuse resistant opioids utilizing the Company's patented proprietary technology, and a once-daily opioid. They are sustained release oral formulations of opioids for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse. Elite also provides contract manufacturing for Actavis and Ascend Laboratories (previously a subsidiary of ThePharmaNetwork and now a subsidiary of Alkem Laboratories Ltd.) and has partnered with Mikah Pharma to develop a new product, with Hi-Tech Pharmacal to develop an intermediate for a generic product, and a Hong Kong based company to develop a branded product for the United States market and its territories. Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ.
:) CBAI is an excellent stock $$$$$
$CBAI has just triggered the "Parabolic SAR Buy Signals" scan criteria at Stockcharts.com
~ http://tinyurl.com/SAR-BUY ~
Cord Blood America Announces 2013 First Quarter Financial Results
LAS VEGAS, May 15, 2013 /PRNewswire/ -- Cord Blood America, Inc. (www.cordblood-america.com) (OTC Bulletin Board: CBAI) ("CBAI" or the "Company") today announced financial results for the quarter ended March 31, 2013.
First Quarter 2013 Highlights From Continuing Operations
Recurring revenues increased approximately 7% for the three months ended March 31, 2013 to $740,124.
Cash provided by operations totaled $128,970 in the first quarter. This represents 68% of the total full year cash generated in 2012 of $190,323.
EBITDA for the quarter increased 587% to $99,985 from $14,542 in the year ago period.
SG&A decreased 11% to $1.11 million from $1.24 million in the year ago period.
Our cash balance increased 40% to $369,186 compared to the same period a year ago.
MediSwipe Inc. Announces First eCommerce Sales of Hemp Based Energy Drink "Chillo" on Amazon.com
LOS ANGELES, June 13, 2013 /PRNewswire/ -- MediSwipe Inc. (www.MediSwipe.com) (OTCQB: MWIP), a data management solutions company for the medicinal marijuana and health care industry, today announced that the Company's popular hemp based energy drink "CHILLO" is now for sale with the world's largest online retailer on Amazon.com Marketplace. With the trusted Amazon platform and fulfillment services, MediSwipe expects to experience a surge in orders of the beverage through ecommerce sales as the products profit from enhanced visibility within the Amazon catalog.
"Chillo is a one of a kind product, and can only benefit from being placed in front of tens of millions of potential customers. Amazon.com offers an opportunity to reach a niche market as we can now service customers across North America and abroad. As we expand the brand globally, we are proud to partner with the largest and most successful online marketplace around the world," stated MediSwipe CEO, B. Michael Friedman.
With the dramatic orange color and flavor of CHILLO, and added benefits of hemp, vitamins and caffeine, we are pleased to be able to deliver the product through Amazon.com for those who are not able to access it through our retail network," stated B. Michael Friedman for MediSwipe.
The Company has also announced plans to launch additional online marketing campaigns through its Facebook site for both "Chillo" and C+ Swiss Tea. Starting today, for every 420th "Like" to the Company's Facebook page, the Company will give away a free Chillo and C+Swiss gift pack to that lucky friend.
CHILLO, with its distinct trademark orange can, carries the chill of hemp seed extract with the added punch and perfect blend of caffeine, vitamins B6 and B12 for the ultimate drink experience. Both Chillo and C+ Swiss Hemp Tea are available in dispensaries and select locations across the country, and may be ordered exclusively through MediSwipe by calling 248.262.6850 or through email at info@MediSwipe.com.
About MediSwipe Inc.
MediSwipe Inc. (www.MediSwipe.com) provides innovative patient solutions for electronically processing transactions within the healthcare industry. MediSwipe provides terminal-based service packages and integrated Web Portal add-ons for physicians, clinics, hospitals and medical dispensaries that include: digital patient records, Electronic Referrals, Credit/Debit Card merchant services, Check Guarantee and Accounts Receivable Financing.
Virogen Business Unit, "The Cannabis Connection," Partners With "TheMedMen" to Provide Full Range of Consulting Services to E...
Virogen Inc. (OTC Pink: VRNI), a holding company that owns Tiger Team Technologies and The Cannabis Connection, today announced that it has partnered with California's TheMedMen, a medicinal marijuana consulting firm, in a venture that is intended to bring broader exposure to both firms. VRNI expects that, by venturing with TheMedMen, it will be in a position to gain a foothold in the medical marijuana industry, particularly in the lucrative areas of retail supply, support and consulting. TheMedMen anticipates that its association with a publicly-traded company will serve to increase its profile within the $15-20 billion legal marijuana industry.
"The Marijuana Green Rush has taken on a national scope. We provide consulting to all emerging cannabis markets across the country, so it is a natural next step to partner with a publically traded company to have an even greater reach for our much sought after services," said Monica Burrell, Director of Business Development for TheMedMen.
"We believe that our partnering with TheMedMen will allow us to establish our company within the medicinal marijuana industry as an agent for consolidation of the fragmented industry," said Paul Hogan, President of VRNI. Mr. Hogan continued, "Our plans for consolidation include the acquisition of businesses that are involved in all facets of the industry, including dispensary management, product cultivation, dispensary design and build-out, licensing, product delivery services, branding and marketing." Mr. Hogan noted that the portion of the medicinal marijuana industry outside of dispensary ownership represents approximately $6 billion in annual revenues, an industry segment well worth VRNI's efforts.
About The Med Men
TheMedMen, a self-proclaimed California Grown company, consults on medicinal marijuana projects all over the United States. The areas of TheMedMen's consulting services are cultivation, dispensary design and build-out, licensing, brokering joint ventures, product delivery services, cannabis education, branding and marketing. More information about TheMedMen is available at: www.themedmen.com.
About Virogen, Inc.
In addition to developing its recently announced business unit, The Cannabis Connection, Virogen, Inc. is a technology holding company. The company's wholly owned subsidiary, Tiger Team Technologies "T3," has developed a unique suite of copyrighted tools to address the network and database security needs of enterprise level companies and corporations. T3's risk management offering provides an unprecedented level of security and liability protection, positioning it as one of the only companies with a comprehensive solution to data security breaches for its clients. T3's primary markets include medical service providers, financial services firms, brokerages and currency transaction platforms, consumer credit card companies, banking entities, retailers, defense and government related operations.
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2013, FQ4/13 Revenues Highest in Corp
Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral abuse-resistant controlled release product formulations and the manufacturing of generic pharmaceuticals, announced results for the fiscal year ended March 31, 2013.
Consolidated revenues were $3.4 million for the fiscal year, an increase of $1.0 million or approximately 40% over consolidated revenues for the prior year. Revenues for the quarter ended March 31, 2013, were exceptionally strong, totaling $1.5 million, the highest quarterly revenue level in corporate history, 131% above quarterly revenues for the comparable period of the prior year. The large increases in revenues are the result of the successful launch and strong growth in new product revenues which have mostly been created during the past 18 months.
Since the end of the fiscal year, Elite launched two new products, Phentermine 15mg capsules and Phentermine 30mg capsules, both being distributed under license by TAGI Pharma. These new products did not generate revenues during the fiscal year ended March 31, 2013, but are generating revenues currently. Shortly, Elite will begin manufacture of naltrexone 50 mg tablets, a recently approved ANDA whose revenues are not represented in Elite's fiscal year 2013 results.
Elite's operations incurred a $1.9 million negative cash flow, due in large part to the financing of a $1.4 million increase inventory and receivables generated by the rapid increase in revenues.
Consolidated loss from operations was $1.6 million, and GAAP net income, including non-cash income relating to the accounting treatment of preferred share and warrant derivatives was $1.5 million. Basic earnings per share were $0.00 on a weighted average 349.1 million common shares outstanding. Fully diluted loss per share was $(0.00), on a weighted average of 526.9 million shares outstanding on a fully diluted basis.
Jerry Treppel, Chairman and CEO of Elite commented, "It has been a remarkable year for Elite. We launched new products, substantially increased our revenues, and lowered our operating losses. Most importantly, I can now tell you that we expect our first commercially scaled-up, abuse-resistant opioid product to enter human pilot studies later this year. We have also conducted work on another abuse-resistant opioid product. We have also received FDA feedback on clinical protocols for the extended release brompheniramine product and have filed a Citizen Petition regarding the extended release brompheniramine/pseudoephedrine product, which, if successful, would put this product in a position to also begin clinical trials and eventually secure approvals for bringing these products on to the market. The Company will host a conference call to discuss the results of operations and provide an update on recent business developments on Monday, June 24, 2013 at 11:00 AM EDT. Company executives will also conduct a question and answer session following their remarks.
To access the conference call:
Domestic callers: (800) 346-7359
International callers: (973) 528-0008
Conference Entry Code: 98840
A digital telephone replay will be available approximately one hour after the conclusion of the call for two weeks until July 8, 2013 by dialing:
Domestic callers: (800) 332-6854
International callers: (973) 528-0005
Conference entry code: 98840
The financial statements can be viewed in Elite's Annual Report on Form 10-K at: http://www.elitepharma.com/sec_filings.asp.
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products. Elite's strategy includes assisting partner companies in the life cycle management of products to improve off-patent drug products and developing generic versions of controlled release drug products with high barriers to entry. Elite has five commercial products currently being sold, an additional product approved and soon to be launched, and one additional product under review pending approval by the FDA. Elite's lead pipeline products include abuse resistant opioids utilizing the Company's patented proprietary technology, and a once-daily opioid. They are sustained release oral formulations of opioids for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse. Elite also provides contract manufacturing for Mikah Pharma and Ascend Laboratories (a subsidiary of Alkem Laboratories Ltd.) and has partnered with Mikah Pharma to develop a new product, with Hi-Tech Pharmacal to develop an intermediate for a generic product, and a Hong Kong based company to develop a branded product for the United States market and its territories. Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ.
EPGL Medical Unveils New Devices and Intellectual Property Under EP Global Communications, Inc. Ownership
IRVINE, Jun 18, 2013 (GLOBE NEWSWIRE via COMTEX) - via PRWEB - EP Global Communications, Inc. (the Company), (Stock Ticker: EPGL) EPGL Medical Sciences, is pleased to announce several new devices resulting from the TopSpin technology recently announced. Many of these devices have not been revealed before today. To Compliment the MPDD, the new MPTT will be first to become a prototype this fall and new FDA 510k and PMA Applications are being prepared for filing during 3rd and 4th Quarters. EPGL has filed patents and owns unique Intellectual Property for each of the following new smart medical devices:
1. A new advanced ablation device for nerve pain treatment in the back.
2. A new advanced ablation device for nerve treatment of Facial Glabballar Frowning.
3. A new advanced device for elimination of facial wrinkles.
4. A new advanced Epidural device.
5. A new advanced power source for TopSpin medical devices.
6. A new and promising device for treatment of Retinitis Pigmentosa
7. A new and promising device for treatment of Macular Degeneration
8. A new and promising treatment for Hearing Loss
9. A new more accurate treatment for trigger points in the muscles (MPTT)
10. A new advanced device for treatment of prostate tumors.
11. A new advanced endoscopic device.
12. A new advanced device for delivery of micron sized drug payloads.
13. A new advanced device for delivery of micro mechanical devices into the body.
14. A new advanced device for biopsy.
15. A new advanced device for stem cell treatment delivery.
16. A new advanced contact lens device.
Several more devices beyond this list will be revealed in coming months by the Company. This represents the beginning for EPGL technological development.
About EP Global Communications, Inc. / EPGL Medical
EP Global Communications, Inc. is a medical device manufacturer and marketing company with exclusive rights to a new FDA 510k cleared medical device called the Muscle Pain Detection Device. The MPDD is a revolutionary new diagnostic tool for the detection of muscular originated pain in the human body.
The chart is excellent for CBAI.
Fa$lane I like your post:
~ $CBAI ~ Daily Par Sar Buy Signal ~ Criteria alert triggered during a recent trading session!
$CBAI has just triggered the "Parabolic SAR Buy Signals" scan criteria at Stockcharts.com
~ http://tinyurl.com/SAR-BUY ~
For a more in Depth study and DD profile, similar to the one contained in this link: ~ http://tinyurl.com/DDexample ~
Click the following link and type ticker or brief message asking me about the DD: ~ http://tinyurl.com/GET-THE-DD ~
What does the scan "Parabolic SAR Buy Signals" mean? Below is an image example and study link.
~ http://stockcharts.com/school/doku.php?id=chart_school:technical_indicators:parabolic_sar ~
To find other similar posts of "CBAI" utilize the links that follow.
Search MACDgyver's "Parabolic SAR Buy Signals" posts: ~ http://investorshub.advfn.com/boards/msgsearchbymember.aspx?searchID=251916&srchyr=2013&SearchStr=ParSarBuyScan ~
Search MACDgyver's posts for symbol "CBAI": ~ http://investorshub.advfn.com/boards/msgsearchbymember.aspx?searchID=251916&srchyr=2013&SearchStr=CBAI ~
Search Ihub for "CBAI" posts: ~ http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=CBAI ~
For more in depth training and information visit Chartschool on the Stockcharts page.
~ http://stockcharts.com/school/doku.php?id=chart_school ~
Also don't forget the Ihub Edu Channel.
~ http://investorshub.advfn.com/boards/education.aspx ~
c
Replies:
buyers beware....
Myth on 7/8/2013 7:39:25 PM
Report TOS
EPGL is a solid company with solid growth.
Google Glass to be Integrated by Medical Device Maker EPGL Med and EP Global Communications, Inc.
IRVINE, Apr 11, 2013 (GLOBE NEWSWIRE via COMTEX) - via PRWEB - EP Global Communications, Inc. (the Company), (stock ticker:EPGL) will be among the first Medical Device Makers to Implement Google Glass technology and the API Mirror platform for use with its medical devices. EPGL Medical, a new medical device maker specializing in advanced technology for innovative hand-held medical devices, has several new devices in development under direction of David T. Markus Ph.D., which are being developed with the latest smart platforms in mind. "Physicians using our devices will be able to utilize technology such as Google Glass while performing procedures, using our devices and viewing feedback data in real-time." Said David T. Markus, Ph.D. "The advancement of these exceptional new technologies are ideal for medical applications as doctors need a hands-free reference to feedback data while performing procedures." Markus said.
In addition to integrating smart technology such as Google Glass, EPGL Medical now has a "secret weapon" medical device technology advancement which no other medical device company has. This single technology will be the catalyst for dozens of new medical device technologies to be produced or licensed by the Company. The Company is in the process of filing more than 50 patents to protect this unique and valuable innovation. "It so happens that our new devices are being developed right at the same time very cool smart technologies such as Google Glass are in their infancy". Said Company President Michael Hayes. "It makes sense to embrace this technology fully and use it to make EPGL medical devices even smarter. Every new device concept we are developing will benefit from the integration of smart technology."
In addition to the new technologies EPGL is progressing, the Company is implementing an innovative new approach to medical device marketing with a business model which guarantees residual income from each new device sold. The Company's VIP approach to its physician customers with on-going technical support and educational training, will build strong loyalty to our medical devices.
Additionally, EPGL is making it as attractive as possible to purchase our devices by giving doctors and hospitals several affordable options for their purchase including, outright purchase, leasing and financing options. These options combined with the newly established CPT coding for our first device; MPDD, will make it easier than ever for doctors to build a business around EPGL medical devices.
About EP Global Communications, Inc. / EPGL Medical
EP Global Communications, Inc. is a medical device manufacturer and marketing company with exclusive rights to a new FDA 510k cleared medical device called the Muscle Pain Detection Device. The MPDD is a revolutionary new diagnostic tool for the detection of muscular originated pain in the human body.
EP Global Communications, Inc. DTCC Chill Lift is Authorized
IRVINE, Calif., June 25, 2013 /PRNewswire/ -- EP Global Communications, Inc. (the Company), (OTC-PINK: EPGL) is pleased to announce that DTCC counsel has confirmed their authorization for removal of the DTCC Chill on EPGL ticker. The Company is also announcing that it will immediately move to file SEC forms for up-listing the Company to a higher stock exchange. "We have systematically been accomplishing our objectives, starting with the restructuring of the company, becoming OTC Current Information, launching our first medical device and now DTCC Chill lift. We will now move forward with up-listing EPGL to higher stock exchanges," said Michael Hayes, Company CEO. "Our sole focus is to bring incredible Company value and returns to our shareholders and we wish to thank DTCC counsel for their hard work along with that of our own counsel to accomplish this major development," Mr. Hayes added.
About EP Global Communications, Inc. / EPGL Medical
EP Global Communications, Inc. is a medical device manufacturer and marketing company with a world-class team of doctors and scientists on board. The Company is currently marketing its first FDA cleared device with several additional "smart" medical devices under development. The Company is the owner of the cutting edge technological platform for medical device development called "Topspin".
Safe Harbor Statement
EPGL Medical Unveils New Devices and Intellectual Property Under EP Global Communications, Inc. Ownership
IRVINE, Jun 18, 2013 (GLOBE NEWSWIRE via COMTEX) - via PRWEB - EP Global Communications, Inc. (the Company), (Stock Ticker: EPGL) EPGL Medical Sciences, is pleased to announce several new devices resulting from the TopSpin technology recently announced. Many of these devices have not been revealed before today. To Compliment the MPDD, the new MPTT will be first to become a prototype this fall and new FDA 510k and PMA Applications are being prepared for filing during 3rd and 4th Quarters. EPGL has filed patents and owns unique Intellectual Property for each of the following new smart medical devices:
1. A new advanced ablation device for nerve pain treatment in the back.
2. A new advanced ablation device for nerve treatment of Facial Glabballar Frowning.
3. A new advanced device for elimination of facial wrinkles.
4. A new advanced Epidural device.
5. A new advanced power source for TopSpin medical devices.
6. A new and promising device for treatment of Retinitis Pigmentosa
7. A new and promising device for treatment of Macular Degeneration
8. A new and promising treatment for Hearing Loss
9. A new more accurate treatment for trigger points in the muscles (MPTT)
10. A new advanced device for treatment of prostate tumors.
11. A new advanced endoscopic device.
12. A new advanced device for delivery of micron sized drug payloads.
13. A new advanced device for delivery of micro mechanical devices into the body.
14. A new advanced device for biopsy.
15. A new advanced device for stem cell treatment delivery.
16. A new advanced contact lens device.
Several more devices beyond this list will be revealed in coming months by the Company. This represents the beginning for EPGL technological development.
About EP Global Communications, Inc. / EPGL Medical
EP Global Communications, Inc. is a medical device manufacturer and marketing company with exclusive rights to a new FDA 510k cleared medical device called the Muscle Pain Detection Device. The MPDD is a revolutionary new diagnostic tool for the detection of muscular originated pain in the human body.
13. A new advanced device for delivery of micro mechanical devices into the body.
14. A new advanced device for biopsy.
15. A new advanced device for stem cell treatment delivery.
16. A new advanced contact lens device.
Several more devices beyond this list will be revealed in coming months by the Company. This represents the beginning for EPGL technological development.
About EP Global Communications, Inc. / EPGL Medical
EP Global Communications, Inc. is a medical device manufacturer and marketing company with exclusive rights to a new FDA 510k cleared medical device called the Muscle Pain Detection Device. The MPDD is a revolutionary new diagnostic tool for the detection of muscular originated pain in the human body.
For those new to the board: EPGL Medical Unveils New Devices and Intellectual Property Under EP Global Communications, Inc. Ownership
IRVINE, Jun 18, 2013 (GLOBE NEWSWIRE via COMTEX) - via PRWEB - EP Global Communications, Inc. (the Company), (Stock Ticker: EPGL) EPGL Medical Sciences, is pleased to announce several new devices resulting from the TopSpin technology recently announced. Many of these devices have not been revealed before today. To Compliment the MPDD, the new MPTT will be first to become a prototype this fall and new FDA 510k and PMA Applications are being prepared for filing during 3rd and 4th Quarters. EPGL has filed patents and owns unique Intellectual Property for each of the following new smart medical devices:
1. A new advanced ablation device for nerve pain treatment in the back.
2. A new advanced ablation device for nerve treatment of Facial Glabballar Frowning.
3. A new advanced device for elimination of facial wrinkles.
4. A new advanced Epidural device.
5. A new advanced power source for TopSpin medical devices.
6. A new and promising device for treatment of Retinitis Pigmentosa
7. A new and promising device for treatment of Macular Degeneration
8. A new and promising treatment for Hearing Loss
9. A new more accurate treatment for trigger points in the muscles (MPTT)
10. A new advanced device for treatment of prostate tumors.
11. A new advanced endoscopic device.
12. A new advanced device for delivery of micron sized drug payloads.
Tier Change
Thu, Jul 04, 2013 12:00 - Entest BioMedical Inc. (ENTB: OTCQB) - Tier Change - The symbol, ENTB, no longer is classified as OTC Pink Limited. As of Thu, Jul 04, 2013, ENTB resides in the OTCQB tier. You may find a complete list of tier changes at otcmarkets.com.
Tier Change
Sat, Jul 06, 2013 12:00 - Entourage Mining Ltd. (ENMGF: OTCQB) - Tier Change - The symbol, ENMGF, no longer is classified as OTC Pink Limited. As of Sat, Jul 06, 2013, ENMGF resides in the OTCQB tier. You may find a complete list of tier changes at otcmarkets.com.
EPGL Medical Unveils New Devices and Intellectual Property Under EP Global Communications, Inc. Ownership
IRVINE, Jun 18, 2013 (GLOBE NEWSWIRE via COMTEX) - via PRWEB - EP Global Communications, Inc. (the Company), (Stock Ticker: EPGL) EPGL Medical Sciences, is pleased to announce several new devices resulting from the TopSpin technology recently announced. Many of these devices have not been revealed before today. To Compliment the MPDD, the new MPTT will be first to become a prototype this fall and new FDA 510k and PMA Applications are being prepared for filing during 3rd and 4th Quarters. EPGL has filed patents and owns unique Intellectual Property for each of the following new smart medical devices:
1. A new advanced ablation device for nerve pain treatment in the back.
2. A new advanced ablation device for nerve treatment of Facial Glabballar Frowning.
3. A new advanced device for elimination of facial wrinkles.
4. A new advanced Epidural device.
5. A new advanced power source for TopSpin medical devices.
6. A new and promising device for treatment of Retinitis Pigmentosa
7. A new and promising device for treatment of Macular Degeneration
8. A new and promising treatment for Hearing Loss
9. A new more accurate treatment for trigger points in the muscles (MPTT)
10. A new advanced device for treatment of prostate tumors.
11. A new advanced endoscopic device.
12. A new advanced device for delivery of micron sized drug payloads.
13. A new advanced device for delivery of micro mechanical devices into the body.
14. A new advanced device for biopsy.
15. A new advanced device for stem cell treatment delivery.
16. A new advanced contact lens device.
Several more devices beyond this list will be revealed in coming months by the Company. This represents the beginning for EPGL technological development.
About EP Global Communications, Inc. / EPGL Medical
EP Global Communications, Inc. is a medical device manufacturer and marketing company with exclusive rights to a new FDA 510k cleared medical device called the Muscle Pain Detection Device. The MPDD is a revolutionary new diagnostic tool for the detection of muscular originated pain in the human body.
IMO the FDA approves or fast tracks 12hr ER ELI216 Oxy/Nal as a 505b2 NDA based on its CY2013 Human Pilot Studies BEs & PKs patented delivery results vs.
(1) 12hr ER ADT Purdue Oxycontin
(2) 12hr ER ART Pfizer ALO-01 Mor/Nal
(3) 12hr ER ART Pfizer ALO-02 Oxy/Nal
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2013, FQ4/13 Revenues Highest in Corp
Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral abuse-resistant controlled release product formulations and the manufacturing of generic pharmaceuticals, announced results for the fiscal year ended March 31, 2013.
Consolidated revenues were $3.4 million for the fiscal year, an increase of $1.0 million or approximately 40% over consolidated revenues for the prior year. Revenues for the quarter ended March 31, 2013, were exceptionally strong, totaling $1.5 million, the highest quarterly revenue level in corporate history, 131% above quarterly revenues for the comparable period of the prior year. The large increases in revenues are the result of the successful launch and strong growth in new product revenues which have mostly been created during the past 18 months.
Since the end of the fiscal year, Elite launched two new products, Phentermine 15mg capsules and Phentermine 30mg capsules, both being distributed under license by TAGI Pharma. These new products did not generate revenues during the fiscal year ended March 31, 2013, but are generating revenues currently. Shortly, Elite will begin manufacture of naltrexone 50 mg tablets, a recently approved ANDA whose revenues are not represented in Elite's fiscal year 2013 results.
EP Global Communications, Inc, EPGL Medical Begins Selling MPDD Devices, Singapore Distributor Secures First 1,000 Units Off ...
via PRWEB - EP Global Communications, Inc. (the Company), (Pink Sheets:EPGL.PK) is pleased to announce that the Company has begun selling MPDD units both in the US Market and Internationally. The exclusive Singapore distributor has secured the first 1,000 units to come off the assembly line. In addition, the Company is simultaneously engaging the top 20 international markets throughout the world in addition to the United States. "We are aggressively going after all the markets now as of today". Said David T. Markus Ph.D. Vice President of BioMems development. "Shareholders will soon learn our innovative new business model strategy for VIP physicians everywhere. We have taken a page from the Apple / Google marketing playbook. We will be a different kind of medical device company."
About EP Global Communications, Inc.
EP Global Communications, Inc. is a medical device manufacturer and marketing company with exclusive rights to a new FDA 510k cleared medical device called the Muscle Pain Detection Device. The MPDD is a revolutionary new diagnostic tool for the detection of muscular originated pain in the human body.
IRVINE, Jun 18, 2013 (GLOBE NEWSWIRE via COMTEX) - via PRWEB - EP Global Communications, Inc. (the Company), (Stock Ticker: EPGL) EPGL Medical Sciences, is pleased to announce several new devices resulting from the TopSpin technology recently announced. Many of these devices have not been revealed before today. To Compliment the MPDD, the new MPTT will be first to become a prototype this fall and new FDA 510k and PMA Applications are being prepared for filing during 3rd and 4th Quarters. EPGL has filed patents and owns unique Intellectual Property for each of the following new smart medical devices:
1. A new advanced ablation device for nerve pain treatment in the back.
2. A new advanced ablation device for nerve treatment of Facial Glabballar Frowning.
3. A new advanced device for elimination of facial wrinkles.
4. A new advanced Epidural device.
5. A new advanced power source for TopSpin medical devices.
6. A new and promising device for treatment of Retinitis Pigmentosa
7. A new and promising device for treatment of Macular Degeneration
8. A new and promising treatment for Hearing Loss
9. A new more accurate treatment for trigger points in the muscles (MPTT)
10. A new advanced device for treatment of prostate tumors.
11. A new advanced endoscopic device.
12. A new advanced device for delivery of micron sized drug payloads.
13. A new advanced device for delivery of micro mechanical devices into the body.
14. A new advanced device for biopsy.
15. A new advanced device for stem cell treatment delivery.
16. A new advanced contact lens device.
Several more devices beyond this list will be revealed in coming months by the Company. This represents the beginning for EPGL technological development.
About EP Global Communications, Inc. / EPGL Medical
EP Global Communications, Inc. is a medical device manufacturer and marketing company with exclusive rights to a new FDA 510k cleared medical device called the Muscle Pain Detection Device. The MPDD is a revolutionary new diagnostic tool for the detection of muscular originated pain in the human body.
EP Global Communications, Inc. DTCC Chill Lift is Authorized
IRVINE, Calif., June 25, 2013 /PRNewswire/ -- EP Global Communications, Inc. (the Company), (OTC-PINK: EPGL) is pleased to announce that DTCC counsel has confirmed their authorization for removal of the DTCC Chill on EPGL ticker. The Company is also announcing that it will immediately move to file SEC forms for up-listing the Company to a higher stock exchange. "We have systematically been accomplishing our objectives, starting with the restructuring of the company, becoming OTC Current Information, launching our first medical device and now DTCC Chill lift. We will now move forward with up-listing EPGL to higher stock exchanges," said Michael Hayes, Company CEO. "Our sole focus is to bring incredible Company value and returns to our shareholders and we wish to thank DTCC counsel for their hard work along with that of our own counsel to accomplish this major development," Mr. Hayes added.
About EP Global Communications, Inc. / EPGL Medical
EP Global Communications, Inc. is a medical device manufacturer and marketing company with a world-class team of doctors and scientists on board. The Company is currently marketing its first FDA cleared device with several additional "smart" medical devices under development. The Company is the owner of the cutting edge technological platform for medical device development called "Topspin".
EPGL Medical Unveils New Devices and Intellectual Property Under EP Global Communications, Inc. Ownership
IRVINE, Jun 18, 2013 (GLOBE NEWSWIRE via COMTEX) - via PRWEB - EP Global Communications, Inc. (the Company), (Stock Ticker: EPGL) EPGL Medical Sciences, is pleased to announce several new devices resulting from the TopSpin technology recently announced. Many of these devices have not been revealed before today. To Compliment the MPDD, the new MPTT will be first to become a prototype this fall and new FDA 510k and PMA Applications are being prepared for filing during 3rd and 4th Quarters. EPGL has filed patents and owns unique Intellectual Property for each of the following new smart medical devices:
1. A new advanced ablation device for nerve pain treatment in the back.
2. A new advanced ablation device for nerve treatment of Facial Glabballar Frowning.
3. A new advanced device for elimination of facial wrinkles.
4. A new advanced Epidural device.
5. A new advanced power source for TopSpin medical devices.
6. A new and promising device for treatment of Retinitis Pigmentosa
7. A new and promising device for treatment of Macular Degeneration
8. A new and promising treatment for Hearing Loss
9. A new more accurate treatment for trigger points in the muscles (MPTT)
10. A new advanced device for treatment of prostate tumors.
11. A new advanced endoscopic device.
12. A new advanced device for delivery of micron sized drug payloads.
Quote:
Company Vice President - BioMems Development
David T. Markus Ph.D.
David T. Markus holds a Ph.D. in Biomedical Engineering and a MS in Electrical Engineering with an emphasis in MEMS Microelectronics and Biomedical. Dr. Markus spent 11 years with Raytheon and holds 8 US patents and has 9 other US Patents Pending. He has been involved in research for several of the world's leading technological institutions, including the Office of Naval Research in Arlington, Virginia, NASA Jet Propulsion Laboratory in Pasadena, CA and he has been published 15 times for various technical conferences. He was a principal investigator on SBIR DARPA Phase I and Phase II, and "Ultraflexible Substrate" for Macroelectronics Program by Dr. Robert Reuss at DARPA. He has been involved in the engineering and the development on seven surgical devices, including devices for Cataract surgery, Intra-Ocular Lens Delivery, Arthroscopy, Endodontic Endoscope, Micro Endoscope and Neural Electrodes. Additionally he was instrumental on developing three medical laboratory devices, including for In-Vitro Fertilization, PCR instrumentation and drug discovery. Finally, Dr. Markus is fluent in English, Chinese-Madarin, Taiwanese-FuJian and Indonesian languages. A full bio for Dr. Markus will be made available on the Company website in the near future
EPGL Medical Unveils New Devices and Intellectual Property Under EP Global Communications, Inc. Ownership
IRVINE, Jun 18, 2013 (GLOBE NEWSWIRE via COMTEX) - via PRWEB - EP Global Communications, Inc. (the Company), (Stock Ticker: EPGL) EPGL Medical Sciences, is pleased to announce several new devices resulting from the TopSpin technology recently announced. Many of these devices have not been revealed before today. To Compliment the MPDD, the new MPTT will be first to become a prototype this fall and new FDA 510k and PMA Applications are being prepared for filing during 3rd and 4th Quarters. EPGL has filed patents and owns unique Intellectual Property for each of the following new smart medical devices:
1. A new advanced ablation device for nerve pain treatment in the back.
2. A new advanced ablation device for nerve treatment of Facial Glabballar Frowning.
3. A new advanced device for elimination of facial wrinkles.
4. A new advanced Epidural device.
5. A new advanced power source for TopSpin medical devices.
6. A new and promising device for treatment of Retinitis Pigmentosa
7. A new and promising device for treatment of Macular Degeneration
8. A new and promising treatment for Hearing Loss
9. A new more accurate treatment for trigger points in the muscles (MPTT)
10. A new advanced device for treatment of prostate tumors.
11. A new advanced endoscopic device.
12. A new advanced device for delivery of micron sized drug payloads.
13. A new advanced device for delivery of micro mechanical devices into the body.
14. A new advanced device for biopsy.
15. A new advanced device for stem cell treatment delivery.
16. A new advanced contact lens device.
Several more devices beyond this list will be revealed in coming months by the Company. This represents the beginning for EPGL technological development.
About EP Global Communications, Inc. / EPGL Medical
EP Global Communications, Inc. is a medical device manufacturer and marketing company with exclusive rights to a new FDA 510k cleared medical device called the Muscle Pain Detection Device. The MPDD is a revolutionary new diagnostic tool for the detection of muscular originated pain in the human body.
Google Glass to be Integrated by Medical Device Maker EPGL Med and EP Global Communications, Inc.
IRVINE, Apr 11, 2013 (GLOBE NEWSWIRE via COMTEX) - via PRWEB - EP Global Communications, Inc. (the Company), (stock ticker:EPGL) will be among the first Medical Device Makers to Implement Google Glass technology and the API Mirror platform for use with its medical devices. EPGL Medical, a new medical device maker specializing in advanced technology for innovative hand-held medical devices, has several new devices in development under direction of David T. Markus Ph.D., which are being developed with the latest smart platforms in mind. "Physicians using our devices will be able to utilize technology such as Google Glass while performing procedures, using our devices and viewing feedback data in real-time." Said David T. Markus, Ph.D. "The advancement of these exceptional new technologies are ideal for medical applications as doctors need a hands-free reference to feedback data while performing procedures." Markus said.
In addition to integrating smart technology such as Google Glass, EPGL Medical now has a "secret weapon" medical device technology advancement which no other medical device company has. This single technology will be the catalyst for dozens of new medical device technologies to be produced or licensed by the Company. The Company is in the process of filing more than 50 patents to protect this unique and valuable innovation. "It so happens that our new devices are being developed right at the same time very cool smart technologies such as Google Glass are in their infancy". Said Company President Michael Hayes. "It makes sense to embrace this technology fully and use it to make EPGL medical devices even smarter. Every new device concept we are developing will benefit from the integration of smart technology."
In addition to the new technologies EPGL is progressing, the Company is implementing an innovative new approach to medical device marketing with a business model which guarantees residual income from each new device sold. The Company's VIP approach to its physician customers with on-going technical support and educational training, will build strong loyalty to our medical devices.
Additionally, EPGL is making it as attractive as possible to purchase our devices by giving doctors and hospitals several affordable options for their purchase including, outright purchase, leasing and financing options. These options combined with the newly established CPT coding for our first device; MPDD, will make it easier than ever for doctors to build a business around EPGL medical devices.
About EP Global Communications, Inc. / EPGL Medical
EP Global Communications, Inc. is a medical device manufacturer and marketing company with exclusive rights to a new FDA 510k cleared medical device called the Muscle Pain Detection Device. The MPDD is a revolutionary new diagnostic tool for the detection of muscular originated pain in the human body.